Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Increased by Raymond James Trust N.A.

Raymond James Trust N.A. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,134 shares of the biopharmaceutical company’s stock after buying an additional 2,154 shares during the quarter. Raymond James Trust N.A.’s holdings in Gilead Sciences were worth $3,099,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rockefeller Capital Management L.P. grew its stake in shares of Gilead Sciences by 3.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 142,703 shares of the biopharmaceutical company’s stock worth $10,361,000 after purchasing an additional 4,480 shares during the last quarter. Mutual Advisors LLC grew its stake in shares of Gilead Sciences by 9.2% in the 4th quarter. Mutual Advisors LLC now owns 20,841 shares of the biopharmaceutical company’s stock worth $1,513,000 after purchasing an additional 1,753 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of Gilead Sciences by 3.9% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 17,428 shares of the biopharmaceutical company’s stock worth $1,265,000 after purchasing an additional 648 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $73,000. Finally, LPL Financial LLC grew its stake in shares of Gilead Sciences by 7.7% in the 4th quarter. LPL Financial LLC now owns 767,837 shares of the biopharmaceutical company’s stock worth $55,753,000 after purchasing an additional 54,957 shares during the last quarter. 78.58% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ GILD opened at $63.77 on Friday. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $79.93 billion, a PE ratio of 19.44, a price-to-earnings-growth ratio of 0.61 and a beta of 0.31. The company has a 50 day moving average price of $63.22 and a two-hundred day moving average price of $62.02. Gilead Sciences, Inc. has a 12-month low of $57.17 and a 12-month high of $74.12.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.07. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $5.88 billion. Gilead Sciences had a net margin of 15.03% and a return on equity of 42.92%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.63 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 89.02%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 target price on the stock. Truist Financial lifted their target price on shares of Gilead Sciences from $71.00 to $76.00 and gave the stock a “hold” rating in a research report on Thursday, September 15th. BMO Capital Markets started coverage on shares of Gilead Sciences in a research report on Tuesday, June 7th. They issued a “hold” rating and a $63.00 target price on the stock. Piper Sandler lifted their target price on shares of Gilead Sciences from $74.00 to $79.00 in a research report on Monday, September 12th. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, July 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $73.53.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.